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Fig. 1. Schematic structure of Stathmin 1 protein. The catastrophe 
promotion region at the N-terminal region, the tubulin binding 
domain at its C-terminal region and the four serine sites of phos-
phorylation (S16, S25, S38 and S63) are illustrated. The amino 
acid positions are indicated.
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Stathmin 1 is a microtubule destabilizer that plays an impor-
tant role in cell cycle progression, segregation of chromo-
somes, clonogenicity, cell motility and survival. Stathmin 1 
overexpression has been reported in malignant hematopoietic 
cells and Stathmin 1 inhibition reduces the highly proliferative 
potential of leukemia cell lines. However, during the differen-
tiation of primary hematopoietic cells, Stathmin 1 expression 
decreases in parallel to decreases in the proliferative potential 
of early hematopoietic progenitors. The scope of the present 
review is to survey the current knowledge and highlight future 
perspectives for Stathmin 1 in normal and malignant hemato-
poiesis, with regard to the expression, function and clinical 
implications of this protein. [BMB Reports 2014; 47(12): 
660-665]
STATHMIN 1 INTEGRATES MULTIPLE SIGNALING 
PATHWAYS
Stathmin 1 is a cytoplasmastic phosphoprotein of 18 kDa, also 
known as Oncoprotein 18 (OP18), Leukemia-associated phos-
phoprotein p18 (LAP18) or Metablastin, which belongs to the 
Stathmin family. All members of this family share a Stathmin- 
like domain that contains up to four serine phosphorylation 
sites (residues 16, 25, 38 and 68) at the N-terminal region and 
a tubulin-binding domain (1, 2). The schematic representation 
of Stathmin 1 is illustrated in Fig. 1. The main function of 
Stathmin 1 is based on the microtubule destabilizer activity of 
this protein, which enables the promotion of a microtubule 
catastrophe or the sequestration of alpha/beta-tubulin hetero-
dimers, preventing the formation of microtubules (3-5). The 
name “Stathmin” derives from “Stathmos” which means 
“relay”, the protein received this name due to its role in the 
signal transduction of multiple signaling pathways summarized 
in Fig. 2 (6, 7).
　Phosphorylation of Stathmin 1 at specific serine sites (16 
and/or 63) reduces the affinity between Stathmin 1 and al-
pha/beta-tubulin heterodimers and represents an important 
mechanism of its regulation (8). During mitosis, accurate mi-
crotubule dynamics are necessary for the success of cell cycle 
progression and multiple signaling pathways participate in this 
process, targeting Stathmin 1 at serine sites. Aurora kinase B, 
Protein kinase A (PKA), P21 Protein (Cdc42/Rac)-Activated 
Kinase (PAK1) and Ca2+/calmodulin-dependent protein kinases 
(CamKs) may phosphorylate Stathmin 1 at serine 16 and/or 63, 
resulting in potent inactivation of tubulin binding capacity (9). 
Cyclin-dependent kinases (CDKs), Mitogen-activated protein 
kinases (MAPKs) and phosphoinositide 3-kinase (PI3K) induce 
Stathmin 1 phosphorylation at serine 25 and/or 38, which is 
not sufficient to inhibit the association between alpha/beta-tu-
bulin and Stathmin 1. Stathmin 1 may be dephosphorylated by 
the phosphatase proteins, including Protein phosphatase 2A 
(PP2A), Protein phosphatase 2B (PP2B) and Phosphoprotein 
phosphatase 1 (PP1) (10-12). In addition to the functions of 
Stathmin 1 in cell cycle progression, this protein also partici-
pates in the correct segregation of chromosomes, clonoge-
nicity and cell motility and survival of normal and cancer cells 
(8).
　Noteworthy, many of the signaling pathways that modulate 
Stathmin 1 function have been implicated in hematopoiesis-re-
lated processes. The PI3K and MAPK signaling network regu-
lates cell proliferation, survival and differentiation during nor-
mal and malignant hematopoiesis events (13, 14). CDKs regu-
lation of cell cycle progression and transcription is well estab-
lished in hematological malignancies and provides a ther-
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Fig. 2. Stathmin 1 signaling pathway. 
Cyclin-dependent kinases (CDKs), Mito-
gen-activated protein kinases (MAPKs), 
phosphoinositide 3-kinase (PI3K), Aurora 
kinase B (AURKB), Protein kinase A 
(PKA), and Ca2+/calmodulin-dependent 
protein kinases (CamKs) phosphorylate 
Stathmin 1 at serine sites and modu-
late its association with alpha/beta-tu-
bulin heterodimers. Protein phospha-
tase 2A (PP2A), Protein phosphatase 2B
(PP2B) and Phosphoprotein phospha-
tase 1 (PP1) dephosphorylate Stathmin 
1. The alternation in the phosphoryla-
tion and dephosphorylation status of 
Stathmin 1 contributes to the regula-
tion of microtubule dynamics. Abbre-
viations: TKR, tyrosine kinase receptor; 
P, phosphorylation; Ac, acetylation.
apeutic opportunity (15, 16). Overexpression of Aurora kinase 
B has been associated with the progression of myelodysplastic 
syndromes (MDS) (17) and has been observed in acute mye-
loid leukemia (AML), chronic myeloid leukemia, acute lym-
phoblastic leukemia, multiple myeloma, aggressive non-Hodgkin 
lymphoma and Hodgkin lymphoma. Furthermore, Aurora kin-
ase inhibitors appear to have a promising role in hemato-
logical malignancies (18). 
STATHMIN 1 IN NORMAL HEMATOPOIESIS
The role of Stathmin 1 in hematopoiesis was initially ad-
dressed using myeloid leukemia cell lines. Stathmin 1 down-
regulation was reported during chemically-induced mega-
karyocytic differentiation of K562 and HEL cells and its in-
hibition resulted in higher differentiation ability and increased 
polyploidization (19). In addition, Stathmin 1 overexpression 
increased the endomitotic cycles, modulating the propensity 
for polyploidization (20). In contrast, Chang and colleagues 
(21) reported that high levels of unphosphorylated Stathmin 1 
were required for efficient polyploidization during the mega-
karyocyte differentiation induced by PMA treatment. These 
findings may be explained by differences in the chemical in-
ductor, drug concentration, time of treatment and limited abil-
ity of immortalized cell lines to finalize megakaryocytic 
differentiation. In murine hematopoietic cells, the expression 
of Stathmin 1 is high in immature megakaryocytes, low in ma-
ture megakaryocytes and undetectable in platelets, corroborat-
ing the hypothesis that Stathmin 1 is downregulated during 
megakaryocytic maturation (19). More recently, Iancu-Rubin 
and colleagues (22) reported an elegant mechanistic study on 
Stathmin 1 in the human megakaryocytopoiesis using lenti-
viral-mediated Stathmin 1 overexpression in primary CD34+ 
cells, and Stathmin 1 overexpression reduced megakaryocyte 
polyploidization and platelet production (22). 
　Rabilloud and colleagues (23) described an increased 
Stathmin 1 expression during erythroid differentiation. Stathmin 
1 was identified as highly expressed in murine and human er-
ythroleukemia cells submitted to chemically-induced erythroid 
differentiation. These results were confirmed using normal hu-
man primary hematopoietic cells induced to erythroid differ-
entiation, in vitro, with erythropoietin. Interestingly, the high-
est level of Stathmin 1 was observed in primary proerythro-
blasts, compared with erythroblasts, and was not detectable in 
mature erythrocytes. These findings indicate that Stathmin 1 
may be related to the higher proliferative ability of early eryth-
roid progenitors (23).
　There is little evidence of a role for Stathmin 1 in monocytic 
and granulocytic differentiation. Stathmin 1 was first identified 
as a rapidly phosphorylated protein in HL60 cells in response 
to PMA treatment for monocytic differentiation (24). Latterly, 
Johnson and colleagues (25) reported a gradual decrease in 
Stathmin 1 levels and phosphorylation during monocytic and 
granulocytic HL60 cell differentiation induced by physio-
logical agents (D3 vitamin and ATRA plus G-CSF), in parallel 
with decreased cell proliferation. 
　Finally, stathmin 1-knockout mice present two human-like 
hematopoietic disorder phenotypes: megaloblastic anemia and 
thrombocytosis (26). These findings are in agreement with the 
previous evidence for Stathmin 1 function in megakaryocyto-
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Fig. 3. Schematic representation of the role of Stathmin 1 in hema-
topoietic cell differentiation. This model is based on studies that 
evaluated Stathmin 1 during primary hematopoietic cell differentia-
tion (22, 23), especially megakaryocytic (MK) and erythroid differ-
entiation. Stathmin 1 expression is high in proliferating myeloid 
progenitors and is downregulated during cell differentiation. 
poiesis and erythropoiesis (22, 23). A model of Stathmin 1 ex-
pression and relationship with hematopoietic cell differentia-
tion, based on results using primary cells models, is illustrated 
in Fig. 3. 
STATHMIN 1 IN MALIGNANT HEMATOPOIESIS
The early discoveries regarding Stathmin 1 were closely linked 
to the differential expression of this protein in acute leukemia, 
and Stathmin 1 was at that time named as leukemia-associated 
phosphoprotein p18 (27). As previously mentioned, Stathmin 
1 was initially identified in HL60 leukemia cells during mono-
cytic differentiation (24). Hanash and colleagues, using two-di-
mensional PAGE, identified a 18 kDa polypeptide overex-
pressed in primary acute leukemia cells, regardless of their lin-
eage (28), and then cloned and sequenced the Stathmin 1 
gene (29), and characterized the expression pattern in lympho-
cytes induced to proliferate with PHA, EBV-transformed lym-
phoid cells and Jurkat leukemia cells (30, 31). This group also 
reported that Stathmin 1 phosphorylation correlated with 
white blood cell counts and the percentage of cells in the S 
phase in a cohort of 177 childhood acute leukemia patients, 
by two-dimensional PAGE (32). Roos and colleagues (33) de-
scribed an abnormal expression of Stathmin 1 in high grade 
lymphoma and acute leukemia, however no correlation with 
cells at S phase was found. Recently, Stathmin 1 was reported 
to be highly expressed in bone marrow hematopoietic cells in 
a cohort of 79 patients with acute leukemia, corroborating pre-
vious findings (34). 
　In MDS patients, Stathmin 1 expression was found to be 
highly expressed in bone marrow cells from high-risk disease 
individuals, compared to low-risk individuals, and Stathmin 1 
expression positively correlated with bone marrow blast per-
centages in a cohort of 65 MDS patients (34). Another study, 
focused on the identification of biomarkers of human aging 
and aging-related diseases, reported Stathmin 1 to be a protein 
highly expressed in the plasma of MDS patients, compared to 
healthy donors (35). However, the biological functions of 
Stathmin 1 in the plasma have not yet been addressed.
　Importantly, Stathmin 1 silencing resulted in a marked in-
hibition of tumorigenicity of the chronic myeloid leukemia cell 
line K562 in vitro and in a mouse model, suggesting that high 
levels of Stathmin 1 are necessary for the maintenance of the 
leukemia phenotype (36). Iancu-Rubin's group confirmed that 
knockdown of Stathmin 1 reduced K562 cell proliferation (37). 
Using lentiviral-mediated Stathmin 1 silencing, our group showed 
that Stathmin 1 inhibition reduced cell proliferation and clono-
genicity capacity of acute myeloid leukemia U937 cells and 
acute lymphoid leukemia Namalwa cells (34).
　With regard to lymphoid neoplasms, Stathmin 1 was found 
to be overexpressed in lymphoma cell lines compared with 
non-transformed lymphoblastoid cells (38), and in primary ma-
lignant lymphomas compared with normal lymphoid tissue 
(39). Using the microarray approach, Stathmin 1 was identified 
as one of the 15 most relevant genes for determining the out-
come in myeloma multiple patients (41). Recently, Marafioti 
and colleagues (40), using high-throughput immunohisto-
logical screening, identified Stathmin 1 as a marker for follicu-
lar lymphoma. Stathmin 1 expression was absent or very low 
in normal lymphoid tissues, but it was highly expressed in 
97% of the follicular lymphoma samples, including BCL-6 neg-
ative cases. Strong Stathmin 1 expression correlated with a 
high histological grade of the disease. The authors also sug-
gested the use of Stathmin 1 expression as potentially useful 
for diagnosis of CD10 negative follicular lymphoma (40). 
Notably, studies using the expression of Stathmin 1 as a poten-
tial diagnostic tool are scarce in hematological malignancies 
and more studies in this research field are necessary.
FUTURE PERSPECTIVES FOR STATHMIN 1 IN 
HEMATOLOGY
Malignant hematological diseases are characterized by the de-
regulation of multiple signaling pathways, rendering the devel-
opment of an efficient therapy difficult. In this sense, Stathmin 1 
integrates several signaling pathways, many of them described 
to be altered in malignant hematopoietic cells, especially acute 
leukemia and myelodysplastic syndromes. Overexpression of 
Stathmin 1 activity may reduce the fidelity of chromosome seg-
regation by interference in the metaphase-to-anaphase transition 
and causes chromosomal instability (42), a common finding in 
hematological malignancies. Stathmin 1 knockout mice present 
thrombocytosis, a typical clinical finding of some myeloprolifer-
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ative disorders (26). 
An important point to be clarified is whether Stathmin 1 is a 
“driver” or a “passenger” during the malignant transformation 
of hematopoietic cells. There is limited evidence of the trans-
formation capacity of Stathmin 1 from normal to malignant 
cells. The expression of Stathmin 1 carrying Q18E mutation 
exerted transforming activity on 3T3 mouse fibroblasts, result-
ing in vitro foci formation and in vivo tumor growth in im-
munodeficient mice (43). Conversely, BCR/ABL-induced ma-
lignant transformation resulted in a marked increase of stath-
min 1 expression in BaF3 cells, indicating that stathmin 1 may 
contribute to the transformed phenotype (44).
Focusing on Stathmin 1 as a potential therapeutic target, 
there is enough in vitro and in vivo evidence to indicate 
Stathmin 1 as a target for cancer treatment (8), however the 
translation from basic to clinical studies is lacking. Shi and col-
leagues (45) identified a novel small molecule compound 
(GDP366), with a dual inhibitor activity of Survivin and 
Stathmin 1, at mRNA levels. GDP366 was capable of inhibit-
ing the growth of tumor cells in vitro and in vivo. Using a 
small hairpin RNA approach in vivo, Phadke and colleagues 
(46) tested the safety and antitumor efficacy of these molecules 
in rats and in a human tumor xenograft mouse model, respec-
tively. Interestingly, the treatment with small hairpin RNA was 
able to reduce tumor growth in the model used and presented 
systemic safety at the therapeutic dose. These promising find-
ings had potential for the development of more specific in-
hibitors of Stathmin 1 and are shielded the fact that of stathmin 
1 knockout mice are viable and present few alterations, sug-
gesting the possibility of low systemic toxicity.
CONCLUSION
Emerging findings regarding the function of Stathmin 1 in nor-
mal and malignant hematopoiesis are helping to understand 
relevant biological mechanisms. Recent basic science studies 
have shown that Stathmin 1 inhibition in cancer cells has been 
successful in reducing the proliferative phenotype of malignant 
cells. Therefore, strategies targeting Stathmin 1 in malignant 
hematopoietic cells represent an interesting field of investiga-
tion. 
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